Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock

Amylyx Pharmaceuticals (AMLX) released Phase 3 LUCIDITY trial results for avexitide, a treatment for post-bariatric hypoglycemia. Shares rose 15.7% after-hours. The trial's success could validate Amylyx's shift to endocrine disease, while failure may refocus attention on earlier-stage programs. The company has $250.8M in cash, sufficient until 2028. Avexitide has Breakthrough Therapy designation, with a potential 2027 launch if approved.

Mizuho named Amylyx Pharmaceuticals a top small/midcap biotech pick, raising its price target 40% to $42 after positive Phase 3 trial results for avexitide. Guggenheim and H.C. Wainwright also raised targets to $55. The company aims for US regulatory filing by 2026 and potential 2027 launch.

Amylyx (AMLX) reported a 55% reduction in severe post-bariatric hypoglycemia events in its Phase 3 LUCIDITY trial of avexitide. The company plans to submit avexitide for FDA approval by the end of 2026. AMLX also filed an offering to sell 14.09M shares at $35.50, aiming to raise ~$471.7M for avexitide's U.S. launch, manufacturing, and R&D.

Iovance Biotherapeutics (IOVA) surged 12% to a 52-week high after reporting Q2 revenue of $99.3M and a UBS price target raise. Amylyx Pharmaceuticals (AMLX) rose 2% on positive Phase 3 trial results and a $500M offering. ConocoPhillips (COP) gained 3% after strong Q2 earnings and a Morgan Stanley price target increase.

Amylyx Pharmaceuticals' shares rose 63.8% after positive phase III study results for avexitide, a treatment for post-bariatric hypoglycemia. The study met primary and secondary endpoints, with a 55% reduction in hypoglycemic events. The company plans to file for FDA approval by the end of 2026. Avexitide has Breakthrough Therapy designation and, if approved, could launch commercially in 2027, providing Amylyx with its first marketed drug.

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.